FDA Expands Dupixent Use as Questions About Rare Lymphoma Continue
The FDA has expanded Dupixent's use to additional pediatric patients while continuing to review reports of cutaneous T-cell lymphoma. Researchers, regulators, and attorneys are closely watching developments involving the widely prescribed medication.





